LABD Rises +16% in 30 Days as Biotech Stocks Pull Back

Key Takeaways

• LABD surged approximately 16% over the last 30 days, reflecting a sharp pullback in US biotechnology stocks that the fund inversely tracks with -3x daily leverage.
• Over the last quarter, LABD declined roughly 31%, as a powerful biotech rally from late May through mid-July crushed the inverse leveraged position.
• The recent biotech selloff was driven by high-profile earnings disappointments, including ALNY's revenue guidance cut, alongside broader risk-off rotation away from high-beta growth sectors.
• The S&P Biotechnology Select Industry Index — which LABD inversely tracks — saw its equal-weighted constituents come under pressure as clinical setbacks, regulatory headwinds, and hawkish Federal Reserve signals weighed on investor sentiment.
• LABD's leveraged inverse structure means the fund is designed for short-term tactical positioning, not buy-and-hold investing, and its daily reset mechanism amplifies both gains and losses.

Understanding LABD: The -3x Biotech Inverse ETF

LABD is a leveraged inverse exchange-traded fund managed by Direxion, a division of Rafferty Asset Management. The fund seeks daily investment results, before fees and expenses, that correspond to -300% of the daily performance of the S&P Biotechnology Select Industry Index. In practice, when the underlying biotech index declines by 1% on a given day, LABD aims to rise by approximately 3%, and vice versa.

The fund achieves its inverse leveraged exposure primarily through swap agreements, futures contracts, and other derivatives tied to the biotech index. Its portfolio holdings consist largely of cash equivalents, US Treasury instruments, and total return swaps — not direct short positions in individual biotech stocks. The net expense ratio stands at 1.07%, and assets under management have fluctuated around $60 million to $87 million in recent months.

The underlying S&P Biotechnology Select Industry Index is an equal-weighted benchmark comprising roughly 130 to 140 US-listed biotechnology companies spanning market capitalizations from small-cap to large-cap. Top constituents include APGE, MRNA, TWST, KYMR, and VKTX, among others. Because the index is equal-weighted, smaller and mid-cap biotech names exert outsized influence on performance relative to market-cap-weighted benchmarks, increasing the index's volatility — and, by extension, LABD's amplified price swings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

LABD's Recent Price Performance: 30 Days vs. Quarter

Over the last 30 days, LABD climbed approximately 16%, rising from a closing price near $7.95 in early July to approximately $9.24 by late July. The move was not linear: the fund experienced pronounced daily swings characteristic of leveraged inverse products, with intra-period drawdowns and surges reflecting the underlying index's bouts of volatility. The 30-day advance marked a meaningful recovery from multi-month lows reached in early July, when LABD traded below $7.00.

Over the last quarter, however, LABD posted a decline of roughly 31%, tumbling from levels around $13.40 in late May. The quarterly loss underscores the powerful biotech rally that unfolded from late spring through mid-July, during which the S&P Biotechnology Select Industry Index delivered strong double-digit gains. For an inverse leveraged fund, sustained directional moves in the underlying benchmark compound daily returns in ways that can significantly erode value over multi-week holding periods, a dynamic known as volatility decay.

Drivers Behind LABD's 30-Day Gain

LABD's 30-day advance was fueled by a notable deterioration in biotechnology sector sentiment during July. The most consequential single event was ALNY's second-quarter earnings report, which triggered a single-day stock decline of approximately 28%. The company surprised investors by lowering full-year revenue guidance for its transthyretin (TTR) amyloidosis franchise by $200 million, citing a normalization of growth following the initial launch surge of Amvuttra. The move erased roughly $11 billion in market capitalization and rippled across the biotech space.

Compounding the pressure, DHR trimmed its core revenue growth outlook, with its biotechnology segment revenue falling short of analyst estimates. The life sciences tools giant's cautious commentary on customer project timing raised broader concerns about biotech R&D spending momentum. Separately, CAPR experienced a severe decline after an FDA advisory committee voted 9-3 that the company had not demonstrated substantial evidence of cardiac benefit for its Duchenne muscular dystrophy therapy candidate.

Macroeconomic forces added further headwinds. The Federal Reserve held interest rates steady at its late-July meeting, but three voting members supported a rate hike, and policymakers emphasized that progress toward the 2% inflation target had stalled. The hawkish tone pressured rate-sensitive growth sectors, including biotechnology, where future cash flows are discounted more heavily in higher-rate environments. A broader rotation out of high-beta, high-duration assets amplified the biotech selloff, directly benefiting LABD's inverse positioning.

Quarterly Performance Drivers for LABD

LABD's quarterly decline of approximately 31% reflects the inverse of a powerful biotechnology sector rally that dominated from late May through mid-July. The S&P Biotechnology Select Industry Index rallied sharply during this window, driven by robust enthusiasm around obesity and metabolic drug development, a resurgence in antibody-drug conjugate dealmaking, and multiple high-value merger-and-acquisition announcements. The equal-weighted structure of the index meant that mid-cap and small-cap biotech names — which surged disproportionately — exerted significant upward pressure.

The XBI ETF, which tracks the same index, rose from roughly $128 in early June to above $164 by mid-July, a gain exceeding 28%. For LABD's -3x inverse structure, this sustained upward trend produced compounding losses that far exceeded three times the index's inverse return over the period, illustrating the daily reset mechanism's impact during trending markets. Institutional and retail inflows into biotech ETFs during the second quarter further reinforced the bullish price action that pressured LABD.

LABD ETF Outlook: What to Watch Next

The trajectory of LABD in the coming months will depend heavily on whether the recent biotech weakness extends or reverses. Key earnings reports from major index constituents, including further updates from large-cap biopharma names, will be critical in shaping sector sentiment. Alnylam's credibility overhang following its guidance cut may take time to resolve, and markets will scrutinize prescription trend data for Amvuttra and competing TTR therapies from PFE and BBIO.

On the macroeconomic front, the Federal Reserve's policy path remains the dominant variable. If inflation proves sticky and rate-cut expectations continue to be pushed further into the future, high-duration biotech names may face additional valuation compression — a scenario that would benefit LABD's inverse positioning. Conversely, any dovish pivot or favorable inflation data could reignite the risk-on bid for biotech and pressure LABD. Investors should also monitor biotech clinical catalysts scheduled for the second half of 2026, including data readouts at major medical conferences, as positive trial results could swiftly reverse sector momentum. Regulatory developments at the FDA, including pending drug approval decisions, represent additional binary events capable of driving sharp index-level moves. Given LABD's daily reset mechanism and the inherent volatility of the biotechnology sector, the fund remains best suited for short-term tactical use by experienced investors who closely monitor their positions.

AI Screener

One tool I find particularly useful for staying on top of these dynamics is Tickeron’s AI Screener. It helps me quickly scan for patterns and signals across the biotech space and beyond, allowing more precise timing around volatile names like LABD.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Jimmy Landsman|Expert

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.

Industry description